Applying Recent Advances to Personalized Breast Cancer Care, A Breast Surgical Oncologist’s View: Brigid Killelea, MD, FACS

Over recent years, numerous developments have occurred in the fields of breast cancer prevention, genetic testing, screening, and surgical procedures. In this interview, Dr. Brigid Killelea, Medical Director of Breast Surgery at Hartford HealthCare, explains strategies for incorporating these advances into the care of patients with breast cancer.  

Continue reading

Making Strides in Breast Cancer Treatment With Richard Zelkowitz, MD

Significant progress has been made in numerous facets of breast cancer care in recent years, including developments in treatment, imaging, pathology, radiation, and surgery. In this interview, Dr. Richard Zelkowitz, a Regional Medical Director of the Breast Program at Hartford HealthCare, highlights the advances that have been made and explains the importance of subspecialties in ensuring that patients with breast cancer receive the most individualized care possible.  

Continue reading

Guiding Breast Cancer Surgical Decisions With Valerie Brutus, MD, FACS

In this interview with Oncology Data Advisor, Dr. Valerie Brutus, a Breast Surgical Oncologist at St. Vincent's Medical Center, discusses the significance of Magtrace, a liquid tracer which has recently become a game changer in guiding surgical decisions for patients with breast cancer.  

Continue reading

Fam-Trastuzumab Deruxtecan-nxki Approved for Treatment of Breast Cancer

The FDA has approved fam-trastuzumab deruxtecan-nxki (Enhertu®, Daiichi Sankyo, Inc.) for treatment of patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)–positive breast cancer. The approval is specific to individuals who have had prior treatment with an anti–HER2-based regimen in the metastatic, neoadjuvant, or adjuvant setting and have developed disease recurrence within six months of completing therapy. "Although HER2-targeted therapies have improved dise...

Continue reading

Bridging Disparities in Breast Cancer Morbidity and Mortality in Women of Color With Jessica Jones, MD

At the recent American Society of Clinical Oncology (ASCO) Annual Meeting, Jessica Jones, Assistant Professor of Oncology at the University of Texas (UT) Health System, sat down with Oncology Data Advisor to discuss her work in cancer detection and cancer prevention in Black women with a higher risk of developing breast cancer and bridging the racial gap in breast cancer morbidity and mortality with early detection and prevention.

This podcast episode was recorded live at the 2022 ASCO Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed.

Continue reading

Guiding Breast Cancer Surgical Decisions With Valerie Brutus, MD, FACS

In this interview with Oncology Data Advisor, Dr. Valerie Brutus, a Breast Surgical Oncologist at St. Vincent's Medical Center, discusses the significance of Magtrace, a liquid tracer which has recently become a game changer in guiding surgical decisions for patients with breast cancer.  

Continue reading

Significant Knowledge Gains Acquired for Treating Metastatic Breast Cancer

An educational enduring online activity provided by i3 Health has provided knowledge gains pertaining to enhancing treatment tolerability, adherence, and patient-centered care for metastatic breast cancer. In the United States, breast cancer accounts for approximately 30% of cancer diagnoses among women and is the second-leading cause of cancer death. The American Cancer Society has estimated that in 2022 there will be 287,580 new cases of invasive breast cancer, with 43,250 of these cases resul...

Continue reading

Exploring Treatment Outcomes for Lobular Breast Cancer With Jason Mouabbi, MD

At the recent American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Dr. Jason Mouabbi of MD Anderson Cancer Center presented a poster focused on survival outcomes of patients with invasive lobular carcinoma treated with endocrine therapy plus a CDK4/6 inhibitor, mammalian target of rapamycin (mTOR) inhibitor, or a PI3K inhibitor, in comparison to those with metastatic hormone receptor–positive, human epidermal growth factor receptor 2 (HER2)–negative invasive ductal carcinoma. Afterwards, he sat down with Oncology Data Advisor to explain the implication of the study's results and the need for additional research in the field of lobular breast cancer to improve patient outcomes. 

This podcast episode was recorded live at the 2022 ASCO Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed.  

Continue reading

Sharing the Breast Cancer Journey From Diagnosis to Survivorship With Megan-Claire Chase

At the recent American Society of Clinical Oncology (ASCO) Annual Meeting, Megan-Claire Chase, breast cancer survivor and Breast Cancer Program Director at SHARE Cancer Support, sat down with Oncology Data Advisor to talk about her diagnosis, treatment, and survivorship journey, as well as her advocacy work to empower people living with cancer.

This podcast episode was recorded live at the 2022 ASCO Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed. 

Continue reading

Targeting HRAS Mutations in Breast Cancer With Sam Kareff, MD, MPH

Large population next-generation sequencing of tumors for mutations in certain key oncogenes is an important avenue of research for discovering genes that can predict survival or even support the use of targeted therapies for certain patients. At the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Dr. Sam Kareff, MD, MPH, presented a poster about his research about how mutations in the oncogene HRAS affect prognosis and response to therapy in breast cancer. He determined that certain types of HRAS mutation are associated with poor survival and that patients with these mutations may benefit from targeted therapies.

This podcast episode was recorded live at the 2022 ASCO Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed. 

Continue reading

Olaparib Approved as Adjuvant Treatment for BRCA-Mutated High-Risk Early Breast Cancer

The FDA has approved olaparib (Lynparza®, AstraZeneca) for the adjuvant treatment of patients with deleterious or suspected deleterious germline BRCA–mutated, human epidermal growth factor receptor 2 (HER2)–negative high-risk early breast cancer who have previously received adjuvant or neoadjuvant chemotherapy. Olaparib is a poly–adenosine diphosphate ribose polymerase (PARP) inhibitor and is the first approved medication targeting BRCA mutations in early breast cancer. "Approximately 5% of unse...

Continue reading

Making Strides in Breast Cancer Treatment With Richard Zelkowitz, MD

Significant progress has been made in numerous facets of breast cancer care in recent years, including developments in treatment, imaging, pathology, radiation, and surgery. In this interview, Dr. Richard Zelkowitz, a Regional Medical Director of the Breast Program at Hartford HealthCare, highlights the advances that have been made and explains the importance of subspecialties in ensuring that patients with breast cancer receive the most individualized care possible.  

Continue reading

Applying Recent Advances to Personalized Breast Cancer Care, A Breast Surgical Oncologist’s View: Brigid Killelea, MD, FACS

Over recent years, numerous developments have occurred in the fields of breast cancer prevention, genetic testing, screening, and surgical procedures. In this interview, Dr. Brigid Killelea, Medical Director of Breast Surgery at Hartford HealthCare, explains strategies for incorporating these advances into the care of patients with breast cancer.

Continue reading

Insights Into Breast Cancer Treatment and Management During the COVID-19 Pandemic: Valerie Brutus, MD, FACS

For patients with breast cancer, the approach to treatment requires an individualized approach accounting for factors such as genetic risk, symptom management, and more recently, the challenges of the COVID-19 pandemic. In this interview, Dr. Valerie Brutus, a breast surgical oncologist at St. Vincent's Medical Center of Hartford HealthCare, discusses strategies for successfully incorporating each of these factors into patients' treatment.  

Continue reading

Patients Need Layers of Support: Oncology Nurse Navigation and Its Role in Breast Cancer Care With Judy Herrick, RN, OCN®, ONN-CG

·

In this interview in honor of Breast Cancer Awareness Month, Judy Herrick, RN, OCN®, ONN-CG, the Supervisor of Support Services at UT Southwestern Simmons Comprehensive Cancer Center, discusses the role of oncology nurse navigation and support services in ensuring that patients with breast cancer receive optimal care during their treatment. Ms. Herrick also discusses the importance of patient education and shares strategies for utilizing available resources to address all facets of breast cancer care.

Continue reading

Overcoming Pandemic Challenges in Breast Cancer Care With Erin Prendergast, RN, CBCN®

This latest interview for Breast Cancer Awareness Month features Erin Prendergast, RN, CBCN®, an oncology nurse navigator and Senior Breast Clinical Coordinator in the Breast Cancer Program at UT Southwestern Simmons Comprehensive Cancer Center. Ms. Prendergast explains what she does in her role as an oncology nurse navigator and shares strategies that her team has implemented to ensure that patients with breast cancer receive optimal access to treatment and supportive care during the COVID-19 pandemic.

Continue reading

Developments in Breast Imaging and Radiology: A Conversation With Tricia Trammell

In this interview, Tricia Trammell, BA, CRA, FAHRA, R.T. (R)(M)(QM)(BS), CN-BI, Breast Center Manager at UT Southwestern Simmons Comprehensive Cancer Center, discusses the advancements in breast imaging in relation to screening for breast cancer.


Continue reading

Improving the Management of Metastatic Breast Cancer: A Conversation With Dr. Sara Tolaney

· Keira Smith: Welcome to Oncology Data AdvisorTM, where we explore the latest advances in cancer research and treatment. I'm Keira Smith. In this podcast, Dr. Sara Tolaney from Dana-Farber Cancer Institute will be discussing strategies for improving the management of patients with metastatic breast cancer. Thank you for joining us, Dr. Tolaney. Sara Tolaney, MD, MPH: Thanks so much for having me. I'm Sara Tolaney. I'm a breast medical oncologist at Dana-Farber Cancer Institute here in Bo...

Continue reading

Breast Cancer Genetic Risk and Evaluation With Lillie Shockney, RN, BS, MAS, HON-ONN-CG

·

In honor of Breast Cancer Awareness Month, Lillie Shockney RN, BS, MAS, HON-ONN-CG, Professor of Surgery at Johns Hopkins University and a member of the National Breast Cancer Foundation (NBCF) Medical Advisory Council, discusses the genetic factors that come into play in the development of breast cancer. In addition, she shares advice for which individuals should receive genetic testing and when, as well as strategies for counseling individuals who are undergoing genetic testing. 

Continue reading

Breast Cancer Risk Factors and Prevention With Lillie Shockney, RN, BS, MAS, HON-ONN-CG

·

In honor of Breast Cancer Awareness Month, Lillie Shockney, RN, BS, MAS, HON-ONN-CG, Professor of Surgery at Johns Hopkins University and a member of the National Breast Cancer Foundation (NBCF) Medical Advisory Council, discusses factors in the risk and prevention of breast cancer. Ms. Shockney shares advice for minimizing one's risk of developing breast cancer and explains the genetic factors that can come into play in the development of this disease.

Continue reading

Copyright © 2022 Oncology Data Advisor. All rights reserved.